The WIN Symposium 2025, held on October 3–4, 2025, successfully concluded as an officially endorsed event by the American Society of Clinical Oncology —marking the 14th consecutive year of this prestigious recognition.
Presented as Track 1 of the Advancing Precision Medicine Conference (APM), the symposium, titled ‘Progress and Challenges in Precision Oncology,’ brought together leading experts from around the world to explore the evolving landscape of precision oncology. Discussions highlighted groundbreaking advances in molecular diagnostics and targeted therapies, as well as the ongoing challenges of translating scientific discoveries into meaningful clinical outcomes.
Curated by the WIN Consortium, the symposium was co-chaired by Wafik El-Deiry, MD, PhD, FACP, Chair of the WIN Consortium, and Razelle Kurzrock, MD, FACP, Chief Medical Officer of the Consortium. The event featured distinguished speakers in cancer research, diagnostics, and therapeutic innovation, offering a comprehensive view of how precision medicine continues to reshape oncology across tumor types and care settings.
Wafik El-Deiry, Director of Legorreta Cancer Center at Brown University and Chair of the WIN Consortium in Cancer Personalized Medicine, shared some key highlights from WIN Symposium:
“Great meeting with Nigel Russell this morning just before we opened the 2025 WIN Symposium in collaboration with Advancing Precision Medicine at the convention center in Philadelphia.”
“Great to run into Philip Heifetz, MBA of Atreg Therapeutics and Keith Wharton, Jr., MD PhD at 2025 WIN Symposium in collaboration with Advancing Precision Medicine in Philadelphia.”
“Nigel Russell, Founder and CEO, Advancing Precision Medicine and Molineaux Christopher P., President and Chief Executive Officer, Life Science Pennsylvania welcome attendees of 2025 WIN Symposium to Philadelphia.”
“As Chair of the WIN Consortium in cancer personalized medicine, I had the privilege of welcoming the attendees to the 2025 WIN Symposium in collaboration with Advancing Precision Medicine in Philadelphia.
It was a good opportunity to update on progress made by the WIN Consortium over the last couple of years.”
“Introducing 2019 Nobel Laureate Bill Kaelin as he presents his keynote at the 2025 WIN Consortium in cancer personalized medicine Symposium in collaboration with Advancing Precision Medicine in Philadelphia.”
“Dr. Kaelin gave fantastic Keynote where he spoke about correlations/plausibility and the power of genetics to establish causality, HIF2 targeting, the role of academic scientists as tinkerers, the power of “up assays,” beta-Catenin degraders and combination therapies in VHL disease.”
“Dr. David Spetzler, President of Caris Life Sciences speaks at 2025 WIN Symposium about DNA/RNA and TMB biomarkers, whole exomes, targeted fusions, AI opportunities and gives examples of predictions for patients with pancreatic cancer, lung cancer and breast cancer brain metastases, digital twins, and finding patterns.”
“Drs. Kaelin and Apostolia M Tsimberidou, ask Dr. David Spetzler questions after his presentation at the 2025 WIN Symposium just before Dr. Keith Flaherty steps up to the podium.”
“Dr. Keith Flaherty discussed progress in melanoma clinical trials, predictive factors for outcomes with BRAF/MEK inhibitor therapy, immunotherapy, impact of liver versus lung metastases, adjuvant and neoadjuvant therapy, no benefit from CTLA4 added to PD1 in adj, pseudoprogression.”
“Wonderful panel discussion moderated by Dr. Jeff Elton of ConcertAI with Drs. David Spetzler of Caris Life Sciences and Keith Flaherty at 2025 WIN Symposium in Philly: multimodal testing, radiomics, patient outcomes, refining patient Dx, role of AI in causality assessment, clinical trial designs, reimbursement for AI, collaboration with academic hubs and outlook towards the future discussed.”
“Keynote and first session faculty (Flaherty Mass General Brigham, Jeff Elton ConcertAI, David Spetzler Caris Life Sciences, El-Deiry The Warren Alpert Medical School of Brown University) at 2025 WIN symposium with Dr. Kaelin.”
“Great to see Dr. Sewanti Limaye, Sewanti Limaye, Dr. Jacob Scott, colleagues from The Warren Alpert Medical School of Brown University, including Dr. Benedito A. Carneiro, Sendurai Mani, Liang Cheng, Matthew Hadfield, Dr. Apostolia M Tsimberidou, from MD Anderson Cancer Center, and Milan Radovich, PhD Caris Life Sciences at 2025 WIN Consortium in cancer personalized medicine WIN Symposium at Philly Convention Center.”
“Great to meet Dr. Eric Van Gieson from EPOCH Epigenetics at 2025 WIN Symposium in Philadelphia.”
” Dr. Gabriele Allegri from Johnson and Johnson leads panel discussion of Precision Cancer Consortium of pharma companies with Daryl Pritchard, Shruti Mathur, Keith Flaherty and Kurt Schalper. Great advances but majority of patients don’t access right treatments; biomarker access mixed.”
“Dr. Jacob Scott from Cleveland Clinic speaks at 2025 WIN Consortium in cancer personalized medicine WIN Symposium about personalizing radiotherapy, mapping phenotypes, network theory to predict RT response, analyzing genomic signatures to optimize dose and his recent JCI paper.”
More posts featuring Wafik El-Deiry.
